Biotronik has launched a new cardiac resynchronisation therapy (CRT-P) device, the Evia HF-T pacemaker, in the European market.
Evia HF-T offers remote patient management with Biotronik’s Home Monitoring, as well as detailed data available through the company’s Heart Failure Monitor which allows for faster therapy intervention to relieve asymptomatic symptoms earlier and decrease hospitalisation.
Ferrarotto Hospital, Italy, University of Catania Cardiac pacing and electrophysiology director Valeria Calvi said MR images give essential diagnostic information which impacts important therapeutic decisions and offers clear insights into the progression of the disease.
"Now that Biotronik enables heart failure patients with the Evia HF-T device to undergo MR scans, it is reassuring that patients can benefit from these optimal diagnostic procedures when they should need them during their lifetime," Calvi added.
Christoph Böhmer, Biotronik managing director, said the new Evia HF-T series completes the company’s technologically advanced bradycardia product portfolio.
"Together with its Lumax 740 tachycardia series, Biotronik offers the industry’s broadest portfolio of implantable cardiac devices in brady, tachy and CRT-therapy approved for use with MRI," Böhmer added.
The COMPAS trial demonstrated that Home Monitoring enabled earlier physician interventions by up to four months and delivered a 66% reduction of hospitalisations for atrial arrhythmia and related strokes. The Evia HF-T pacemaker is the first CRT-P device to be approved for use in an MRI environment, the company said.
According to the European Society of Cardiology, heart failure affects around 30 million people in Europe and data from the US reported that heart failure is responsible as a frequent cause of hospitalisation in patients aged 65 years and older.
Image: Biotronik Evia HF-T, the world’s first MRI-approved CRT pacemaker. Photo courtesy of: Biotronik.